CCAAT/enhancer Binding Protein (C/EBP), alpha (CEBPA) (C-Term), (AA 304-330) antibody

Details for Product No. ABIN653431
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Antigen
Synonyms C/EBP-alpha, CEBP, C/ebpalpha, CBF-A, Cebp, DBPCEP, c/ebpa, cb1062, wu:fj20f03, C/EBP, C/EBPalpha, xC/EBP, cC/EBP, C/EBP alpha
Epitope
C-Term, AA 304-330
(25), (20), (12), (12), (8), (7), (4), (3), (2), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
Reactivity
Human, Mouse (Murine)
(123), (83), (82), (38), (37), (25), (13), (2), (2), (2), (1), (1), (1)
Host
Rabbit
(106), (18), (2)
Clonality (Clone)
Polyclonal ()
Conjugate
Un-conjugated
(4), (4), (4), (3), (3), (3), (3), (3), (3), (3), (3), (1), (1), (1)
Application
Western Blotting (WB), Flow Cytometry (FACS)
(94), (50), (31), (30), (18), (14), (8), (6), (5), (2), (2), (1), (1)
Pubmed 3 references available
Quantity 400 µL
Options
Shipping to United States (Change)
Availability Will be delivered in 2 to 3 Business Days
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Catalog No. ABIN653431
291.50 $
Plus shipping costs $45.00

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen This CEBPA antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 304-330 AA from the C-terminal region of human CEBPA.
Clone RB23215
Isotype Ig
Specificity This CEBPA antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 310~339 amino acids from the C-terminal region of human CEBPA.
Predicted Reactivity Cow (Bovine),Rat (Rattus)
Purification This antibody is purified through a protein A column, followed by peptide affinity purification.
Alternative Name CEBPA
Background CEBPA is a bZIP transcription factor which can bind as a homodimer to certain promoters and enhancers. It can also form heterodimers with the related proteins CEBP-beta and CEBP-gamma. This protein has been shown to bind to the promoter and modulate the expression of the gene encoding leptin, a protein that plays an important role in body weight homeostasis. Also, the protein can interact with CDK2 and CDK4, thereby inhibiting these kinases and causing growth arrest in cultured cells.
Synonyms: CCAAT/enhancer-binding protein alpha, C/EBP alpha, CEBPA
Molecular Weight 37561 DA
Gene ID 1050
UniProt P49715
Research Area Signaling, Protein Modifications, Transcription Factors
Application Notes WB = 1:1000, FACS = 1:10-50
Restrictions For Research Use only
Format Liquid
Concentration 0.5 mg/mL
Buffer PBS with 0.09 % (W/V) sodium azide
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage 4 °C/-20 °C
Storage Comment Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.
Expiry Date 6 months
Supplier Images
anti-CCAAT/enhancer Binding Protein (C/EBP), alpha (CEBPA) (C-Term), (AA 304-330) antibody Western blot analysis of CEBPA Antibody (C-term) (ABIN653431) in mouse liver tissue lysates (35 µg/lane). CEBPA (arrow) was detected using the purified polyclonal antibody.
Background publications Nanri, Uike, Kawakita et al.: "A family harboring a germ-line N-terminal C/EBPalpha mutation and development of acute myeloid leukemia with an additional somatic C-terminal C/EBPalpha mutation." in: Genes, chromosomes & cancer, Vol. 49, Issue 3, pp. 237-41, 2010 (PubMed).

Burnett, Hills, Green et al.: "The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and C" in: Blood, Vol. 115, Issue 5, pp. 948-56, 2010 (PubMed).

Dufour, Schneider, Metzeler et al.: "Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome." in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 28, Issue 4, pp. 570-7, 2010 (PubMed).

Validation Images
Did you look for something else?
back to top